What this trial studies
The aim of the study is to determine the effect Dry Needling of on insulin resistance in obese postmenopausal women.
Conditions in scope
- Insulin Resistance-abdominal Fats -Post Menopausal Women
Interventions
- Dry Needle (Other) — Dry Needle has been used to treat obesity. Clinical research has found that it is particularly effective for abdominal fat loss.Dry needling in the abdominal region requires an in-depth understanding of the underlying anatomy due to significant safety risks.
- abdominal exercises, and medical standard care for insulin resistance (Other) — To reduce belly fat, combine core-strengthening exercises like planks, bicycle crunches, and leg raises with overall fat-burning cardio (walking, running) and a healthy diet
Who can join
All sexes · Ages 48 Years to 60 Years
Inclusion criteria
- All participants post-menopausal from at least 3 years.
- All participants' ages will be ranged from 48-60 years old.
- All participants BMI will exceed 25-30 kg/m2.
- All participants waist hip ratio will be equal or more than 0, 90.
Exclusion criteria
- Surgical liposuction within the last 12 months.
- Untreated hypo- or hyperthyroidism.
- Uncontrolled liver, kidney or cardiovascular disease or diabetes.
- Implanted pacemaker or metal implant.
- History of thrombophlebitis, any hematological disease.
- No past or present neurological and musculoskeletal disorders that will have affected health condition.
- No smoking and drinking habits.
- No psychological problems.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Cairo | Shymaa Mohammed | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2025-01-01
- Primary completion: 2025-04-01
- Last update posted: 2026-01-26
- First posted: 2026-01-26
Sponsor & contact
Lead sponsor: Cairo University (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- HOMA-IR (4 months)
Outcome measures, HOMA-IR (Homeostasis Model Assessment) will be used to assess insulin resistance. HOMA-IR is a model of interactions between glucose and insulin dynamics that is then used to predict fasting steady-state glucose and insulin concentrations for a wide range of possible combinations of insulin resistance and β-cell function.
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07365878 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.